



**ForwardHealth** **ALERT**  
Wisconsin serving you

**TO**

Hospital Providers, HMOs and Other Managed Care Programs

**REGARDING**

New COVID-19-Related Inpatient Procedure Codes

### COVID-19-Related Inpatient Procedure Codes

In response to the COVID-19 public health emergency, the Centers for Medicare & Medicaid Services are implementing 21 new inpatient procedure codes for hospital providers to describe the introduction or infusion of therapeutics and vaccines for COVID-19.

For dates of service on and after January 1, 2021, ForwardHealth will accept and process inpatient hospital claims with the following International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) codes without prior authorization when they are administered in accordance with current U.S. Food and Drug Administration guidance.

ICD CODE	DESCRIPTION
XW013H6	Introduction of other new technology monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6
XW013K6	Introduction of leronlimab monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6
XW013S6	Introduction of COVID-19 vaccine dose 1 into subcutaneous tissue, percutaneous approach, new technology group 6
XW013T6	Introduction of COVID-19 vaccine dose 2 into subcutaneous tissue, percutaneous approach, new technology group 6
XW013U6	Introduction of COVID-19 vaccine into subcutaneous tissue, percutaneous approach, new technology group 6

PROCEDURE CODE	DESCRIPTION
XW023S6	Introduction of COVID-19 vaccine dose 1 into muscle, percutaneous approach, new technology group 6
XW023T6	Introduction of COVID-19 vaccine dose 2 into muscle, percutaneous approach, new technology group 6
XW023U6	Introduction of COVID-19 vaccine into muscle, percutaneous approach, new technology group 6
XW033E6	Introduction of etesevimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033F6	Introduction of bamlanivimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033G6	Introduction of REGN-COV2 monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033H6	Introduction of other new technology monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033L6	Introduction of CD24Fc immunomodulator into peripheral vein, percutaneous approach, new technology group 6
XW043E6	Introduction of etesevimab monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043F6	Introduction of bamlanivimab monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043G6	Introduction of REGN-COV2 monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043H6	Introduction of other new technology monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043L6	Introduction of CD24Fc immunomodulator into central vein, percutaneous approach, new technology group 6
XW0DXM6	Introduction of baricitinib into mouth and pharynx, external approach, new technology group 6
XW0G7M6	Introduction of baricitinib into upper GI, via natural or artificial opening, new technology group 6
XW0H7M6	Introduction of baricitinib into lower GI, via natural or artificial opening, new technology group 6